CTOs on the Move

IsoPlexis

www.isoplexis.com

 
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.isoplexis.com
  • 35 NorthEast Industrial Road
    Branford, CT USA 06405
  • Phone: 475.221.8402

Executives

Name Title Contact Details

Funding

IsoPlexis raised $25M on 05/14/2019
IsoPlexis raised $20M on 01/09/2020
IsoPlexis raised $50M on 01/07/2021
IsoPlexis raised $85M on 01/07/2021

Similar Companies

Cloudbreak

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Our mission is to help people see life better through medicine.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.

Pure Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE`s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate (SDC)- based antimicrobials, represent innovative advances in diverse markets and lead today`s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area).

Axcella Health

Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.

InMed Diagnostics

InMed Diagnostics is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.